Edrok Formulation Private Limited
About Edrok Formulation Private Limited
Data last updated:
Edrok Formulation Private Limited is a private limited company based in Aurangabad, Maharashtra, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 06 May 2022.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U24230MH2022PTC382099. Its GSTIN is 27AAHCE0281D1ZY (Maharashtra).
The company has an authorised share capital of ₹41 Lakh and a paid-up capital of ₹41 Lakh. It is led by directors Rahul Bhaurao Korade and Vijeta Rahul Korade.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Plot No. A – 14 MIDC Waluj, Aurangabad, Maharashtra, India – 431001.
As per the financials filed for FY 2025, the company reported a revenue of ₹3.37 Cr, a growth of 55% compared to the previous year. For the same year it recorded a net profit of ₹7.8 Lakh (net margin 2.3%) and EBITDA of ₹47.96 Lakh (EBITDA margin 14.2%).
As per MCA filings, the company has open charges of ₹4.89 Cr on record.
- EmailLocked
- TelephoneLocked
- WebsiteLocked
- Social MediaLocked
- Registered AddressPlot No. A – 14 MIDC Waluj, Aurangabad, Maharashtra, India – 431001
- IndustryPharma, Drug Formulation & Development
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Business Activity of Edrok Formulation Private Limited
The main business activity of Edrok Formulation is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | Locked |
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Financials of Edrok Formulation Private Limited FY 2025 filings available
Edrok Formulation Private Limited reported revenue of ₹3.37 Cr (up 55% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR) of Edrok Formulation Private Limited
Revenue rose 55% in the latest year. EBITDA rose 21% in the latest year. All are worked out from the filed statements.
Financial Statement Summary of Edrok Formulation Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|
| Profit and Loss Statement | |||
| Revenue from Operations | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• |
| Total Revenue | •••• | •••• | •••• |
| Cost of Materials Consumed | •••• | •••• | •••• |
| Employee Benefit Expense | •••• | •••• | •••• |
| Finance Costs | •••• | •••• | •••• |
| Depreciation and Amortisation | •••• | •••• | •••• |
| Other Expenses | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• |
| EBITDA | ₹47.96 Lakh | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• |
| Tax Expense | •••• | •••• | •••• |
| Net Profit (PAT) | ₹7.8 Lakh | •••• | •••• |
| Balance Sheet | |||
| Share Capital | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• |
| Net Worth (Total Equity) | •••• | •••• | •••• |
| Long-term Borrowings | •••• | •••• | •••• |
| Short-term Borrowings | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• |
Financial Ratios of Edrok Formulation Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|
| Profitability | |||
| EBITDA Margin | 14.2% | •••• | •••• |
| Net Profit Margin | 2.3% | •••• | •••• |
| Return on Equity (ROE) | •••• | •••• | •••• |
| Return on Capital Employed (ROCE) | •••• | •••• | •••• |
| Return on Assets (ROA) | •••• | •••• | •••• |
| Liquidity and Debt | |||
| Current Ratio | •••• | •••• | •••• |
| Quick Ratio | •••• | •••• | •••• |
| Debt-to-Equity Ratio | •••• | •••• | •••• |
| Interest Coverage Ratio | •••• | •••• | •••• |
| Efficiency and Growth | |||
| Asset Turnover | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• |
| Payable Days | •••• | •••• | •••• |
| Inventory Days | •••• | •••• | •••• |
| Revenue Growth | •••• | •••• | •••• |
| Net Profit Growth | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Edrok Formulation are in the company report.
Financial statements from FY 2023
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Peer Comparison of Edrok Formulation Private Limited
Edrok Formulation Private Limited is compared with the companies closest to it by revenue in the Pharma industry (Formulations). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| JVS Healthcare Private Limited | ₹3.4 Cr (FY 2025) | •••• | •••• | 398.0% | •••• | Civil Lines, Delhi, India |
| Maxzimaa Pharmaceuticals Private Limited | ₹3.4 Cr (FY 2025) | •••• | •••• | 0.0% | •••• | New Delhi, Delhi, India |
| Saach Pharmaceuticals Private Limited | ₹3.39 Cr (FY 2024) | •••• | •••• | 17.0% | •••• | Manimajra, Chandigarh, India |
| JC Lifecare Private Limited | ₹3.38 Cr (FY 2025) | •••• | •••• | 6.0% | •••• | New Delhi, Delhi, India |
| Bio Trans Pharmaceuticals Private Limited | ₹3.37 Cr (FY 2024) | •••• | •••• | -8.0% | •••• | Athipattu, Tamil Nadu, India |
| Edrok Formulation Private Limited this company | ₹3.37 Cr (FY 2025) | •••• | •••• | 55.0% | •••• | Aurangabad, Maharashtra, India |
| Aragen Biologics Private Limited | ₹3.37 Cr (FY 2025) | •••• | •••• | 1092.0% | •••• | Hyderabad, Telangana, India |
| Eshwar Pharmaceuticals Private Limited | ₹3.36 Cr (FY 2018) | •••• | •••• | -35.0% | •••• | Hyderabad, Telangana, India |
| Patco Healthcare Private Limited | ₹3.36 Cr (FY 2024) | •••• | •••• | 4.0% | •••• | Kolhapur, Maharashtra, India |
| Vesta Biotech Private Limited | ₹3.36 Cr (FY 2025) | •••• | •••• | -4.0% | •••• | Karnal, Haryana, India |
| Apdm Pharmaceuticals Private Limited | ₹3.36 Cr (FY 2024) | •••• | •••• | •••• | Ahmedabad, Gujarat, India |
Peers are the five companies nearest above and the five nearest below Edrok Formulation by revenue in the Pharma industry (Formulations), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Board of Directors of Edrok Formulation Private Limited
Edrok Formulation has 2 current directors and 1 former director. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Rahul Bhaurao Korade | Director | 06 May 2022 | 4 Years 5 Months | Current |
| Vijeta Rahul Korade Also directs: Elaj Remedies (India) Pvt Ltd | Director | 10 Aug 2024 | 2 Years 2 Months | Current |
Charges & Borrowings of Edrok Formulation Private Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 16 Nov 2024 | Others | ₹2.9 Cr | Open |
| 24 Nov 2022 | Others | ₹1.99 Cr | Open |
Total charge records: 2 View all charges
Employees and EPFO Compliance at Edrok Formulation Private Limited
Employment history and EPFO contributions of people linked to Edrok Formulation.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
Recent Activity on Edrok Formulation Private Limited
Edrok Formulation Private Limited has 3 board changes on record since 2022: 2 appointments and 1 cessation. The latest: Swapnil Raosaheb Shelke ceased to be Director on 12 Aug 2024.
Credit Ratings, Litigation & Regulatory Alerts for Edrok Formulation Private Limited
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Edrok Formulation Private Limited
MSME payment history
Amounts due to small suppliers, the reasons given and MSME-1 filings are in the company report.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Edrok Formulation Private Limited
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Edrok Formulation Private Limited
Edrok Formulation has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AAHCE0281D1ZY | Maharashtra | Active | 01 Jan 2023 |
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Edrok Formulation Private Limited
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Edrok Formulation Private Limited
Edrok Formulation is an active private limited company based in Aurangabad, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 06 May 2022 (4+ years old) and is registered under CIN U24230MH2022PTC382099.
Edrok Formulation reported revenue of ₹3.37 Cr for FY 2025 (up 55% YoY).
Edrok Formulation has 2 current directors:
- Rahul Bhaurao Korade - Director
- Vijeta Rahul Korade - Director
Edrok Formulation reported a net profit of ₹7.8 Lakh (net margin 2.3%) and EBITDA of ₹47.96 Lakh (EBITDA margin 14.2%) for FY 2025, as per its filed financial statements.
The GSTIN of Edrok Formulation is 27AAHCE0281D1ZY, registered in Maharashtra.
The CIN (Corporate Identification Number) of Edrok Formulation is U24230MH2022PTC382099. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Edrok Formulation was incorporated on 06 May 2022, making it 4+ years old. It is registered with the Registrar of Companies, Mumbai.
The peers of Edrok Formulation by revenue are JVS Healthcare Private Limited, Maxzimaa Pharmaceuticals Private Limited, Saach Pharmaceuticals Private Limited, JC Lifecare Private Limited, Bio Trans Pharmaceuticals Private Limited and 5 more, all in the Pharma industry (Formulations).
Swapnil Raosaheb Shelke ceased to be Director on 12 Aug 2024. Vijeta Rahul Korade was appointed as Director on 10 Aug 2024. Rahul Bhaurao Korade was appointed as Director on 06 May 2022.
The registered office of Edrok Formulation is at Plot No. A – 14 MIDC Waluj, Aurangabad, Maharashtra, India – 431001.
Edrok Formulation has an authorised share capital of ₹41 Lakh and a paid-up capital of ₹41 Lakh.